Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System. The study supports the Company’s FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine.

The study, conducted with CenExel Clinical Research, Inc. and following FDA guidance and ICH GCP (International Council for Harmonisation Good Clinical Practice) Guidelines, was designed to evaluate whether a range of external contaminants and substances commonly encountered in daily life and workplace environments affect the accuracy and reliability of the Intelligent Fingerprinting Drug Screening System. These included hand creams, alcohol-based products, oils, dirt, and water. The objective of the study was to demonstrate that the presence of these substances on a donor's fingertip does not impact test results. The protocol assessed the system's ability to maintain codeine specificity across multiple collection time points. Data analysis is underway, with independent verification of results via liquid chromatography-tandem mass spectrometry (“LC-MS/MS”) analysis.